Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial-Reference-Cited by-同舟云学术

Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial

Published:2023-01 Issue:1 Volume:10 Page:e24-e34
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Jabbour Elias,Short Nicholas J,Jain Nitin,Huang Xuelin,Montalban-Bravo Guillermo,Banerjee Pinaki,Rezvani Katayoun,Jiang Xianli,Kim Kun Hee,Kanagal-Shamanna Rashmi,Khoury Joseph D,Patel Keyur,Kadia Tapan M,Daver Naval,Chien Kelly,Alvarado Yesid,Garcia-Manero Guillermo,Issa Ghayas C,Haddad Fadi G,Kwari Monica,Thankachan Jennifer,Delumpa Ricardo,Macaron Walid,Garris Rebecca,Konopleva Marina,Ravandi Farhad,Kantarjian Hagop

Funder

Amgen

Takeda Oncology

Publisher

Elsevier BV

Subject

Hematology

Reference25 articles.

1. Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms;Short;Leukemia,2021

2. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia;Ravandi;Cancer,2015

3. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia;Daver;Haematologica,2015

4. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL;Rousselot;Blood,2016

5. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance;O'Hare;Cancer Cell,2009

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Significance of Measurable Residual Disease in Adult Philadelphia Chromosome–Positive ALL: A GRAAPH-2014 Study;Journal of Clinical Oncology;2024-09-10

2. Cerebrospinal fluid distribution and pharmacokinetics of ponatinib in Ph1+ acute lymphoblastic leukemia;Blood;2024-09-05

3. Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial;Journal of Hematology & Oncology;2024-09-02

4. Design, synthesis and antitumor activity of a novel FGFR2-selective degrader to overcome resistance of the FGFR2V564F gatekeeper mutation based on a pan-FGFR inhibitor;European Journal of Medicinal Chemistry;2024-09

5. The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute lymphoblastic leukemia;Cancer Medicine;2024-09